Black Patients with Metastatic Castrate-Resistant Prostate Cancer Have a Shorter Time Interval Between PSA and Clinical Progression on Novel Hormonal Therapies plus Avelumab

BACKGROUND: Black men are at higher risk for prostate cancer death. Previous studies showed a benefit of different therapies, including immune-based therapy, for Black men with metastatic prostate cancer. We sought to explore the efficacy of the PD-L1 inhibitor avelumab in Black men with metastatic...

Descripción completa

Detalles Bibliográficos
Autores principales: Hawkins, Charlotte (Manogue), Barata, Pedro C, Cotogno, Patrick, Davis, Gaynelle, Jaeger, Ellen, Ledet, Elisa, Miller, Patrick, Lewis, Brian, Sartor, Oliver, Layton, Jodi
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Clinical Trial Results
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020796/
https://www.ncbi.nlm.nih.gov/pubmed/36210487
http://dx.doi.org/10.1093/oncolo/oyac203

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10020796/
https://www.ncbi.nlm.nih.gov/pubmed/36210487
http://dx.doi.org/10.1093/oncolo/oyac203

Ejemplares similares